Sanara MedTech (SMTI) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Sanara MedTech (SMTI) do?
Sanara MedTech Inc (SMTI) is a U.S.-listed company in Healthcare (Medical Instruments & Supplies). What it does: Sells specialized collagen powders and biological implants to surgeons and wound care clinics. Distributes bone fusion products directly to acute care hospitals nationwide. It is worth $300.00M on the market and sold $111.94M over the last year.
- Market cap
- $300.00M
- P/E ratio
- None (reported a loss)
- Annual sales
- $111.94M
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Brief updated
- Nov 15, 2026
Brands and businesses behind SMTI
- CellerateRX: Sells hydrolyzed collagen powders and gels to surgeons for acute wound management.
- HYCOL: Generates revenue by selling hydrolyzed collagen dressings for chronic skin wounds and burns.
- Texagen: Sells amniotic tissue allografts that serve as protective barriers in reconstructive surgery.
- Allafuse: Supplies cellular bone matrix products used by orthopedic surgeons during bone fusion procedures.
SMTI’s flags, in plain English
Each flag is a number from Sanara MedTech’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 15, 2026.
Wide Gross Margin
Gross margin of 90.7% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Still Climbing
Sales up 45.9% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.
Insiders Hold
Insiders own 46.9% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.
Debt Is Driving
Heavy debt, 635% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.
1 more green flag and 2 more risk notes open with the free trial. Try it free for 7 days.
Questions about SMTI
How big is Sanara MedTech?
Sanara MedTech’s market cap is $300.00M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $111.94M: what customers paid the company over the last year, before any costs.
What is SMTI’s P/E ratio?
SMTI has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with SMTI?
The business depends heavily on a small group of contract manufacturers to produce its core collagen products. That is one risk on Sanara MedTech’s card. Its first risk flag is Debt Is Driving, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Sanara MedTech’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. SMTI’s filings on SEC.gov. The Margin Monkey is research, not advice.
